Larynx cancer
diseaseOn this page
Also known as cancer of larynxmalignant laryngeal neoplasmmalignant laryngeal tumormalignant laryngeal tumourmalignant larynx neoplasmmalignant larynx tumormalignant larynx tumourmalignant neoplasm of larynxmalignant neoplasm of the larynxmalignant tumor of larynxmalignant tumor of the larynxmalignant tumour of larynxmalignant tumour of the larynx
Summary
Larynx cancer (MONDO:0002352) is a cancer (an umbrella term covering 7 Mondo subtypes) with 1 GWAS associations across 2 studies and 53 clinical trials. Top therapeutic interventions include docetaxel anhydrous, carboplatin, and sacituzumab govitecan. A subtype of respiratory system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 7 Mondo subtypes
- GWAS associations: 1
- Clinical trials: 53
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | larynx cancer |
| Mondo ID | MONDO:0002352 |
| EFO | EFO:1000354 |
| DOID | DOID:2596 |
| ICD-10-CM | C32 |
| ICD-11 | 75194057 |
| NCIT | C7484 |
| SNOMED CT | 363429002 |
| UMLS | C0007107 |
| MedGen | 2868 |
| GARD | 0027604 |
| Anatomy (UBERON) | UBERON:0001737 |
| Is cancer (heuristic) | yes |
Also known as: cancer of larynx · larynx cancer · malignant laryngeal neoplasm · malignant laryngeal tumor · malignant laryngeal tumour · malignant larynx neoplasm · malignant larynx tumor · malignant larynx tumour · malignant neoplasm of larynx · malignant neoplasm of the larynx · malignant tumor of larynx · malignant tumor of the larynx · malignant tumour of larynx · malignant tumour of the larynx
Data availability: 1 GWAS association (2 studies).
Disease family
This is a subtype of respiratory system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › larynx cancer
Related subtypes (8): nasal cavity cancer, tracheal cancer, bronchus cancer, pharynx cancer, pleural cancer, lung cancer, SMARCA4-deficient sarcoma of thorax, paranasal sinus cancer
Subtypes (7): subglottis cancer, laryngeal cartilage cancer, supraglottis cancer, glottis cancer, laryngeal carcinoma, laryngeal sarcoma, aryepiglottic fold cancer
Genetics & variants
GWAS landscape
1 GWAS associations across 2 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs377734957 | 4e-09 | ATXN10 - WNT7B | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90041800 | Jiang L | 2021 | 269 | 456,079 | A generalized linear mixed model association tool for biobank-scale data. |
| GCST90651366 | Liu TY | 2025 | 216 | 231,112 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs377734957 | 22 | 45860371 | C>T | intergenic_variant | ATXN10 - WNT7B | 4e-09 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 53.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 32 |
| PHASE2 | 10 |
| PHASE3 | 4 |
| PHASE1 | 4 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06706401 | PHASE3 | RECRUITING | Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma |
| NCT00158652 | PHASE3 | COMPLETED | Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC |
| NCT00162708 | PHASE2/PHASE3 | COMPLETED | Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC |
| NCT00169182 | PHASE3 | COMPLETED | Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma |
| NCT00359645 | PHASE3 | COMPLETED | Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population |
| NCT03174275 | PHASE2 | ACTIVE_NOT_RECRUITING | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma |
| NCT03759431 | PHASE2 | ACTIVE_NOT_RECRUITING | Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer |
| NCT06039631 | PHASE2 | RECRUITING | Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer |
| NCT07063212 | PHASE2 | RECRUITING | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) |
| NCT07254962 | PHASE2 | NOT_YET_RECRUITING | CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE) |
| NCT00169247 | PHASE2 | COMPLETED | Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation |
| NCT00599131 | PHASE2 | TERMINATED | Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE) |
| NCT01073683 | PHASE2 | UNKNOWN | Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer |
| NCT03082534 | PHASE2 | COMPLETED | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
| NCT03096808 | PHASE2 | COMPLETED | Adaptive Radiotherapy for Head and Neck Cancer |
| NCT03602079 | PHASE1/PHASE2 | COMPLETED | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene |
| NCT00080028 | PHASE1 | TERMINATED | Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer |
| NCT02586207 | PHASE1 | COMPLETED | Pembrolizumab in Combination With CRT for LA-SCCHN |
| NCT03028766 | PHASE1 | COMPLETED | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer |
| NCT04892875 | PHASE1 | WITHDRAWN | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers |
| NCT00965003 | EARLY_PHASE1 | TERMINATED | MRI Laryngeal Imaging With a Surface Coil |
| NCT03452774 | Not specified | RECRUITING | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry |
| NCT04057209 | Not specified | RECRUITING | VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer |
| NCT04368702 | Not specified | RECRUITING | CONFIRM: Magnetic Resonance Guided Radiation Therapy |
| NCT05179824 | Not specified | ACTIVE_NOT_RECRUITING | Tempus Priority Study: A Pan-tumor Observational Study |
| NCT05337631 | Not specified | RECRUITING | Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy |
| NCT05793151 | Not specified | RECRUITING | Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy |
| NCT05798780 | Not specified | ACTIVE_NOT_RECRUITING | The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors |
| NCT00160095 | Not specified | COMPLETED | Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas |
| NCT00600223 | Not specified | COMPLETED | Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches |
| NCT01045057 | Not specified | COMPLETED | Clinical Feasibility of New Tracheoesophageal Puncture Set |
| NCT01084733 | Not specified | COMPLETED | Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer |
| NCT01700647 | Not specified | COMPLETED | Breath Testing in Early and Late Larynx Cancer |
| NCT02757222 | Not specified | COMPLETED | Dose Escalation Versus Standard in Laryngopharyngeal Cancers |
| NCT03292341 | Not specified | COMPLETED | Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients. |
| NCT03479463 | Not specified | TERMINATED | Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy |
| NCT03653039 | Not specified | COMPLETED | Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy |
| NCT03896958 | Not specified | UNKNOWN | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) |
| NCT03942380 | Not specified | UNKNOWN | Cell-free Tumor DNA in Head and Neck Cancer Patients |
| NCT04028479 | Not specified | COMPLETED | The Registry of Oncology Outcomes Associated With Testing and Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DOCETAXEL ANHYDROUS | 4 | 3 |
| CARBOPLATIN | 4 | 2 |
| SACITUZUMAB GOVITECAN | 4 | 1 |
| TRETINOIN | 4 | 1 |
| 5-FLUORONICOTINIC ACID | 3 | 1 |
| ZIMBERELIMAB | 3 | 1 |
| ADAVOSERTIB | 2 | 1 |
| ETRUMADENANT | 2 | 1 |
| TRASTUZUMAB BOTIDOTIN | 2 | 1 |
| CHEMBL1510899 | 0 | 1 |